Cancer Vaccines
Accentia Biopharmaceuticals Announces Unblinding and Analysis of Fast Tracked Phase 3 Trial for BiovaxID
Published in Vaccine Weekly, October 31st, 2007
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) majority owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), announced its regulatory strategy for its Fast Tracked Phase 3 clinical trial of its anti-cancer vaccine for the treatment of Non-Hodgkin's Lymphoma, BiovaxID. The trial was begun by the National Cancer Institute in 2000. The Company performed a data lock in September 2007 and anticipates having a data analysis of unblinded data on the primary endpoint of disease-free survival for BiovaxID completed and publicly disclosed by March of 2008.
BiovaxID has been in human clinical studies since 1993. Non-Hodgkins Lymphoma is an indolent but typically fatal...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2007-10-31)
More Articles from Vaccine Weekly
- Cancer Vaccines
Baylor Research Institute to Collaborate with Mount Sinai School of Medicine to Develop Therapeutic Cancer Vaccines - Cancer Vaccines
Clinical Trial Evaluating Brain Cancer Vaccine is Underway at NYU - Cancer Vaccines
Study: HPV test beats Pap in detecting cervical cancer - Malaria Vaccines
Malaria vaccine is safe, immunogenic and efficacious in young infants - Malaria Vaccines
New Lancet study: Malaria vaccine candidate has promising safety, tolerability profile in infants - Cancer Vaccines
Advaxis Signs Agreement with Cobra for Manufacture of Lovaxin C Vaccine - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
